Circulogene Africa
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Circulogene Africa - overview
Established
2015
Location
Birmingham, AL, US
Primary Industry
Healthcare
About
Circulogene Africa is focused on innovative liquid biopsy solutions that enhance the detection of tumor DNA and RNA alterations, aiding in personalized cancer treatment for patients. Circulogene Africa was founded in 2015 in Birmingham, US. The company specializes in advanced liquid biopsy technologies that facilitate the analysis of cancer-related mutations. The team includes founders Alihan Aktas, Altay Tinar, Chen-Hsiung Yeh, Göksin Özel, Irem Agin, and Scott Rezek, with Altay Tinar and Göksin Özel serving as CEOs.
In March 2018, Marlow Capital acquired Circulogene Africa, but financial terms were not disclosed. Circulogene specializes in advanced liquid biopsy solutions, offering proprietary products such as TumorClear, ImmunoClear, MSI Complete, and Hereditary Panels. TumorClear utilizes NCCN guideline-compliant cfDNA markers, while ImmunoClear uniquely detects plasma cfRNA PD-L1 for insights in NSCLC immunotherapy. MSI Complete employs Promega® MSI technology to enhance sensitivity in identifying microsatellite instability across cancer types.
The company serves oncologists, healthcare providers, and diagnostic laboratories, benefiting over 25,000 cancer patients with its innovative testing methods. Circulogene generates revenue through B2B transactions with healthcare providers and diagnostic laboratories, offering products on a per-test basis. Oncologists can order specific tests, like TumorClear or ImmunoClear, tailored to individual tumor characteristics. Revenue is driven by demand for these diagnostic tools known for expediting treatment decisions.
The flagship products, particularly ImmunoClear and TumorClear, represent a significant portion of its revenue stream, emphasizing high-quality, actionable insights in oncology. Circulogene Africa plans to enhance its product lineup with upcoming releases aimed at improving cancer diagnostics. The company targets expansion into additional international markets by leveraging recent funding received during its acquisition in March 2018. The funding will support the development and launch of new products designed to meet the evolving needs of cancer care globally.
Current Investors
Marlow Capital
Primary Industry
Healthcare
Sub Industries
Molecular Science, Genetics & Gene Therapy, Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment
Website
https://circulogene.com
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Circulogene Africa - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Circulogene Africa | - |
Displaying 1 - 1 of 1
Circulogene Africa - employee data
Circulogene Africa - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Co-Founder | Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.